CERUS CORP (CERS) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Cerus Corporation is a biomedical products company focused on the development and commercialization of the INTERCEPT Blood System, designed to reduce blood-borne pathogens in donated blood components. The filing covers the fiscal year ended December 31, 2025. The company operates in one reportable segment and maintains commercial operations in the U.S., Europe, the Commonwealth of Independent States (CIS), the Middle East, and Latin America. Key products include approved systems for platelets, plasma, and cryoprecipitation (producing INTERCEPT Fibrinogen Complex or IFC), while the red blood cell system remains in development.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $233.8 million | $201.3 million | +16% |
| Product Revenue | $206.1 million | $180.3 million | +14% |
| Government Contract Revenue | $27.7 million | $21.1 million | +31% |
| Gross Profit (Product) | $112.3 million | $99.5 million | +13% |
| Gross Margin (Product) | 55% | 55% | - |
| Net Loss | $(15.6) million | $(21.0) million | -25% (Narrowed) |
| Operating Cash Flow | $4.8 million | $11.4 million | -57% |
| Total Debt | $83.9 million | $84.2 million | -0.4% |
| Cash & Investments | $82.9 million | $80.5 million | +3% |
Note: The company reported a net loss attributable to Cerus Corporation of $15.6 million for 2025, compared to $20.9 million in 2024. Working capital decreased to $73.2 million from $88.9 million in the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 16% year-over-year, driven by a 14% increase in product revenue (primarily U.S. disposable platelet kit sales and IFC sales) and a 31% increase in government contract revenue (due to the new 2024 BARDA agreement).
- Expense Increases: Research and Development (R&D) expenses rose 15% to $67.7 million, driven by red blood cell development costs under BARDA agreements and the new LED-based illuminator. Selling, General, and Administrative (SG&A) expenses increased 7% to $80.9 million due to workforce costs.
- Cash Flow Dynamics: Net cash provided by operating activities decreased to $4.8 million from $11.4 million, primarily due to increased inventory purchases to mitigate supply chain risks, partially offset by a reduction in net loss.
- Debt Structure: Total debt remained relatively flat at approximately $83.9 million. However, $24.3 million of long-term debt was reclassified to short-term due to the amended Term Loan Credit Agreement, impacting working capital.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- Red Blood Cell System: The company is conducting the Phase 3 RedeS study in the U.S., which completed enrollment in 2025 with results expected in late 2026. In the EU, the company resubmitted its MDR application for the red blood cell system in 2025 after a previous closure; the review of the active pharmaceutical ingredient (API) was transferred to the French National Agency for Medicines and Health Products Safety (ANSM). No timeline for certification is provided.
- Commercialization: The company is shifting its IFC sales model from direct hospital sales to selling kits to blood centers. It plans to submit a PMA application for a new LED-based illuminator in mid-2026.
- Liquidity: Management believes current cash, cash equivalents, short-term investments, and expected government contract funding will be sufficient to meet capital requirements for at least the next 12 months.
- Regulatory Delays: Failure to obtain CE Certificates of Conformity for the red blood cell system or FDA approval for the new illuminator could delay commercialization and increase costs.
- Government Contract Dependency: A significant portion of red blood cell development funding relies on BARDA agreements, which can be terminated for convenience or reduced if milestones are not met.
- Supply Chain Concentration: The company relies on sole suppliers (e.g., Fresenius for disposable kits) and faces risks related to component obsolescence and tariffs.
- Debt Covenants: The Term Loan begins amortizing in April 2026 unless restructured or extended, which could negatively impact working capital.
Investor Verification Checklist
- Red Blood Cell Regulatory Status: Verify the current status of the MDR application review with ANSM and the timeline for the U.S. RedeS study results.
- Debt Amortization: Confirm whether the company will restructure its Term Loan or exercise the option to delay amortization before April 1, 2026.
- BARDA Funding: Monitor the execution of the 2024 BARDA Agreement and the achievement of milestones required to unlock the full $188.4 million funding opportunity.
- Inventory Levels: Assess the impact of increased inventory purchases on future cash flow and potential obsolescence risks given the 18-24 month shelf life of products.
- IFC Commercialization: Track the success of the transition from direct hospital sales to the kit sales model with blood centers.